Please assess the completion status of the following clinical trial:

Trial Title: Impact of Hepatitis B Vaccination on HBs Antigenemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBV patients with persistent HBs antigenemia~Exclusion Criteria:~* decompensated liver cirrhosis~* hepatocellular carcinoma~* other causes of liver disease or mixed causes (excessive alcohol consumption,~* autoimmune liver disease~* immunosuppressive drugs~* infection with hepatitis C virus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- chronic HBV with persistent HBsAg (Type: ACTIVE_COMPARATOR): inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA.
- control group (Type: NO_INTERVENTION): A control group (n=100) did not receive HBV vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).